Abstract
BackgroundTofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Cytokines (e.g., interleukin (IL)-2, -4, -7, -15, -21) involved in lymphocyte development, function and...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have